A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive.

ABSTRACT:

Introduction

Buprenorphine is a partial μ-opioid receptor agonist that, unlike full μ-opioid receptor agonists, has been shown to have a ceiling effect on respiratory depression. Buprenorphine buccal film (BBF) is approved by the US Food and Drug Administration for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for whom alternative treatment options are inadequate. This study was conducted to compare the effects of BBF and immediate-release oral oxycodone hydrochloride administration on respiratory drive, as measured by the ventilatory response to hypercapnia (VRH) after drug administration.

Methods

Subjects (N = 19) were men and women, ages 27-41 years, self-identifying as recreational opioid users who were

SUBMITTER: Webster LR 

PROVIDER: S-EPMC7547962 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature